AGH 3.4 -0.31 Vol 112860 AGL 16.45 0.00 Vol 10000 BAS 1.6 0.00 Vol 0 BFM 16.8 0.00 Vol 0 BG23B 98.0002 0.00 Vol 0 BPH 6.75 0.00 Vol 0 DEVON 4.25 0.00 Vol 0 LOM 2.5 0.00 Vol 0 NTB 50 0.50 Vol 12500 ONE 3.15 0.00 Vol 0 POLAR 5 0.00 Vol 0 SOM 16.25 0.00 Vol 0 WHHL 4.06 0.00 Vol 0 WWW 21.5 0.00 Vol 0
Market Open:

Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March

Hamilton, Bermuda – March 7, 2018In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ), parent of Jazz Investments I Limited whose Secured Loan Note Programme is listed on the BSX, announced their participation in two investor conferences.  The filing stated:

 

DUBLIN,March6,2018--JazzPharmaceuticalsplc(Nasdaq:JAZZ)todayannouncedthatthecompanywillbewebcastingitscorporatepresentationsattwoupcominginvestorconferences.

 

·      CowenandCompany38th AnnualHealthcareConferenceinBoston,MAonTuesday,March 13, 2018 at8:00a.m. EDT /12:00p.m. GMT.Bruce Cozadd, chairman andchiefexecutiveofficer,willprovideanoverviewofthecompany and abusinessandfinancialupdate.

·      BarclaysGlobalHealthcareConferenceinMiami,FLonWednesday,March14,2018at8:00a.m. EDT / 12:00 p.m. GMT.Matt Young, executive vice presidentand chieffinancialofficer,willprovidean overviewofthecompanyandabusinessandfinancialupdate.

 

Alive audiowebcast ofeachpresentation may beaccessedfrom theInvestors section ofthe JazzPharmaceuticalswebsiteathttp://www.jazzpharmaceuticals.com.Pleaseconnecttothewebsitepriorto the startof the presentationto ensure adequatetime for anysoftware downloads thatmaybenecessarytolistentothe webcast.

 

An archive of the webcast will be available for atleast one weekfollowing the presentation ontheInvestorssectionofthecompany’swebsiteathttp://www.jazzpharmaceuticals.com.

 

AboutJazzPharmaceuticals

JazzPharmaceuticalsplc(Nasdaq:JAZZ)isaninternationalbiopharmaceuticalcompanyfocusedonimprovingpatients’livesbyidentifying,developingandcommercializingmeaningfulproductsthataddressunmetmedicalneeds.The companyhasadiverseportfolioof productsandproductcandidateswith afocusinthe areasofsleep andhematology/oncology.Inthese areas,JazzPharmaceuticalsmarketsXyrem®(sodiumoxybate)oralsolution,Erwinaze®(asparaginaseErwiniachrysanthemi),Defitelio®(defibrotidesodium)andVyxeos®(daunorubicinandcytarabine)liposomeforinjectionintheU.S.andmarketsErwinase®andDefitelio®(defibrotide)incountriesoutsidetheU.S.Forcountry-specificproductinformation,pleasevisit http://www.jazzpharmaceuticals.com/products.Formoreinformation,pleasevisit http://www.jazzpharmaceuticals.com/andfollowusonTwitterat@JazzPharma.

 

 

 


JazzPharmaceuticalsContacts:

Investors:

KatheeLittrell

VicePresident,InvestorRelationsIreland,+3531 6347887

U.S., +1 650 496 2717

 

Media:

JacquelineKirby

VicePresident,CorporateAffairs&GovernmentRelationsIreland,+3531 6972141

U.S., +1 215 867 4910

TRADING HOURS

08:30-09:00 Price Discovery
09:00-16:30 Continuous Trading

CONTACT DETAILS

TEL: +1 (441) 292 7212
FAX: +1 (441) 292 7619
Email: info@bsx.com

LOCATION

30 Victoria Street
3rd Floor
Hamilton, Bermuda

MAILING ADDRESS

P.O. Box HM 1369
Hamilton HMFX

Disclaimer

 

The information contained in these pages has been obtained from sources which The Bermuda Stock Exchange believes are reliable. However, the accuracy of the information cannot and is not guaranteed and The Bermuda Stock Exchange makes no representation as to its accuracy or completeness. Neither this Web site, nor any information contained herein, constitutes advice or a solicitation to subscribe, purchase or sell any securities. The Bermuda Stock Exchange expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon any part of the contents of this site or any external sites referenced from this website.